Tonix Pharmaceuticals Holding Corp. (TNXP) - 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated May 1, 2026, discloses preliminary operating results for the quarter ended March 31, 2026, and financial condition as of April 30, 2026. The Company is a biopharmaceutical firm with marketed products including Zembrace SymTouch, Tosymra, and TONMYA (launched November 2025).
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Net Revenue | $6.9 million | $2.4 million |
| Net Loss | $40.8 million | $16.8 million |
| Net Cash Used in Operating Activities | $40.2 million | $16.6 million |
| Capital Expenditures | $1.7 million | $0.006 million |
| Cash and Cash Equivalents (as of April 30, 2026) | $185.5 million | N/A |
| Shares Outstanding (as of April 30, 2026) | 15,540,801 | N/A |
Revenue Breakdown: Zembrace SymTouch and Tosymra generated $3.2 million. TONMYA generated $3.7 million in Q1 2026, following $1.4 million in revenue from its November 2025 launch through year-end 2025.
Material Changes
- Revenue Growth: Net revenue increased 187.5% year-over-year, driven primarily by the commercial launch of TONMYA.
- Increased Losses: Net loss more than doubled to $40.8 million, reflecting higher operating costs associated with the new product launch and general operations.
- Cash Burn: Operating cash outflows increased significantly to $40.2 million compared to $16.6 million in the prior year.
- Capital Spending: Capital expenditures rose to $1.7 million from $6,000 in the prior year.
Outlook, Liquidity, and Risks
Liquidity and Funding: The Company holds $185.5 million in cash as of April 30, 2026. Management expects this, combined with $17.4 million raised from equity offerings in Q2 2026, to fund operations into the second quarter of 2027.
Forward-Looking Statements: The financial data presented is preliminary, unaudited, and subject to revision upon completion of the Form 10-Q filing expected on or about May 11, 2026. PricewaterhouseCoopers LLP has not audited or reviewed this information.
Investor Verification Checklist
- Verify the final audited Q1 2026 results in the upcoming Form 10-Q (expected May 11, 2026) to confirm preliminary figures.
- Confirm the exact amount and terms of the $17.4 million equity offering referenced for Q2 2026.
- Monitor the burn rate relative to the $185.5 million cash balance to validate the runway into Q2 2027.
- Review the specific cost drivers contributing to the $40.8 million net loss and increased operating cash usage.